



**TECHNION**  
Israel Institute  
of Technology

**rticc**  
Rappaport  
Technion Integrated Cancer Center

*Cancer  
Cure is  
Born Here*



**D. DAN AND BETTY KAHN**  
HUMAN HEALTH BUILDING

## **Prof. Moshe Elkabets**

The Shraga Segal Department of  
Microbiology and Immunology  
Ben Gurion University of the Negev

Host

**Prof. Amir Orian**  
Rappaport Faculty of  
Medicine

# RTICC SPECIAL GUEST SEMINAR

**16<sup>th</sup> June**  
**12:00-13:00**



**4th Floor seminar Room, The Ruth and  
Bruce Rappaport Faculty of Medicine**

## **"Modulating the Tumor Microenvironment to Restore Immunotherapy Sensitivity"**

In my talk at RTICC, I will highlight how our lab is tackling one of the most pressing challenges in cancer immunotherapy—resistance to anti-PD1 treatment. I will present our recent findings demonstrating that rational therapy combinations can sensitize tumors to anti-PD1, and that the timing and sequencing of treatments significantly impact therapeutic efficacy. I will also discuss our efforts to improve patient selection through better biomarkers and predictive tools, aiming to identify those most likely to benefit from treatment. Finally, I'll introduce our novel therapeutic approach—a bispecific antibody designed to overcome anti-PD1 resistance by engaging the immune system in a more targeted and effective manner. Our work bridges fundamental research with clinical relevance, and we hope it will contribute to the development of more personalized and durable cancer immunotherapies.